ARMP übertreffen die 20 der letzten 38Schätzungen.
53%
Nächster Bericht
Datum des nächsten Berichts
18. März 2026
Estimate forQ4 25(Revenue/ EPS)
$1.53M
/
-$0.19
Implizierte Änderung vonQ3 25(Revenue/ EPS)
+32.01%
/
-74.32%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
+23.89%
/
-371.43%
Armata Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On 12. Nov. 2025, ARMP reported earnings of -0.74 USD per share (EPS) for Q3 25, missing the estimate of -0.42 USD, resulting in a -72.74% surprise. Revenue reached 1.16 million, compared to an expected 1.41 million, with a -17.66% difference. The market reacted with a -4.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -0.19 USD, with revenue projected to reach 1.53 million USD, implying an decrease of -74.32% EPS, and increase of 32.01% in Revenue from the last quarter.
FAQ
What were Armata Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Armata Pharmaceuticals, Inc. Common Stock reported EPS of -$0.74, missing estimates by -72.74%, and revenue of $1.16M, -17.66% below expectations.
How did the market react to Armata Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -4.63%, changed from $6.69 before the earnings release to $6.38 the day after.
When is Armata Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for 18. März 2026.
What are the forecasts for Armata Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 3
analysts, Armata Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.19 and revenue of $1.53M for Q4 2025.